Skip to content
About
Leadership
Executive Team
Board of Directors
Facilities
State Disclosures
Therapeutic Areas Overview
Central Nervous System
Fibromyalgia
Cocaine Intoxication
Migraine
Immunology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Infectious Disease
Mpox (Monkey Pox)
Smallpox
COVID-19
Rare Disease
Prader-Willi Syndrome
Pipeline
Central Nervous System
TNX-102 SL
TNX-1300
TNX-1900
Immunology
TNX-1500
TNX-1700
Infectious Disease
TNX-801
TNX-1800
TNX-4200 CD45
Rare Disease
TNX-2900
Expanded Access Policy
Medicines
Clinical Trials
News & Events
Press Releases
Tonix in the News
Tonix Sponsored News
Investor Presentations
Scientific Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Investor Presentations
Scientific Presentations
Program Specific Presentations
Fact Sheet
Conference Materials
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
Scientific Presentations
April 2025
Sublingual Cyclobenzaprine (TNX-102 SL) for Fibromyalgia: Efficacy and Safety in Two Randomized, Placebo-Controlled Trials
March 2025
Resurrecting Dr. Edward Jenner’s 1796 Horsepox Vaccine to Protect Against Mpox and Smallpox
March 2025
7th International Congress on Controversies in Fibromyalgia March 2025 (Vienna, Austria)
November 2024
Randomized, Double-Blind, Placebo-Controlled Confirmatory Phase 3 Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Fibromyalgia
October 2024
TNX-801 MPOX — A live, attenuated, minimally replicative, MPOX vaccine candidate
September 2024
The importance of
in vitro
discriminatory tests in the development of a sublingual dosage form of TNX-102 SL (Cyclobenzaprine HCl) tablets
September 2024
Pharmacokinetic Properties of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine Hydrochloride
September 2024
Using Synthetic Biology to Battle Mpox
August 2024
MHSRS 2024: Integrating Automated High-Throughput Scratch Assay and Cell Painting for Comprehensive Analysis of Cell Migration and Wound Healing
August 2024
MHSRS 2024: Two Clinical Trials of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Military-Related Posttraumatic Stress Disorder (PTSD) Provide Rationale to Study TNX-102 SL in the Aftermath of Trauma to Reduce Acute Stress Disorder (ASD) and Prevent PTSD
August 2024
MHSRS 2024: Development of the AURORA Platform Trial Network to Test Interventions to Reduce Acute Stress Reaction Symptoms, and Illustration of Use Testing Sublingual Cyclobenzaprine TNX-102 SL
August 2024
MHSRS 2024: TNX-102 SL for Fibromyalgia
August 2024
IASP 2024: Targeting Fibromyalgia Non-Restorative Sleep with Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl): Results of the Positive Phase 3 RESILIENT Trial Consistent with Syndromal Improvement
June 2024
Vaccine Congress 2024: Horsepox: A Live Virus, Single-Dose Vaccine Platform
June 2024
AHS 2024 — American Headache Society Consensus Statement and Other Recommendations: How Many Practitioners Comply With the Recommendations?
June 2024
EULAR 2024 — Targeting Non-Restorative Sleep in Fibromyalgia with Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl) Significantly Improves Pain in RESILIENT, a Confirmatory Phase 3 Randomized Clinical Trial
June 2024
Combined blockade of CD154 and CD28 co-stimulation pathways attenuates pathogenic alloimmunityand prolongs survival in cynomolgus cardiac allografts
June 2024
ATC 2024: Extended Survival of 9- and 10-Gene Edited Pig Heart Xenografts with Ischemia Minimization and CD154 Costimulation Blockade –Based Immunosuppression
June 2024
ATC 2024: Delayed Immune Tolerance for Cardiac Allografts in Nonhuman Primates by Targeting CD154, CD2, and CD28 Costimulation Pathways
June 2024
ASCP Annual Meeting 2024: Effects of Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl) on Mood and Anxiety Symptoms in Fibromyalgia
May 2024
ASCP Annual Meeting 2024: Fibromyalgia-Type Long COVID
May 2024
ASCP Annual Meeting 2024: Acute Stress Disorder
April 2024
AACR Annual Meeting 2024: In Vitro Characterization of a Dual Antagonistic Anti-LILRB2/LILRB4 Monoclonal Antibody
April 2024
World Vaccine Congress 2024
March 2024
American Chemistry Society (ACS) Spring 2024
March 2024
Controversies in Fibromyalgia 2024
March 2024
Controversies in Fibromyalgia
October 2023
Pilot Evaluation of a Clinical Xeno Heart Transplant Regimen in a Preclinical Model
October 2023
Extended Survival of 9- and 10-Gene Edited Pig Heart Xenografts with Ischemia Minimization and CD154 Costimulation Blockade–Based Immunosuppression
October 2023
WVC Europe: A Novel Mpox Vaccine (Horsepox Platform) to Enhance Preparedness and Global Vaccine Equity
October 2023
FPWR: A planned phase 2, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of TNX-2900 for the treatment of patients with Prader-Willi syndrome
September 2023
CICON: mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in Anti-PD-1 Treated CT26.WT Subcutaneous and CT26-Luciferase Orthotopic Syngeneic Colorectal Cancer Models by Targeting MDSCs in BALB/C Mice
September 2023
IHC: Human Trigeminal Ganglia Possess Oxytocin Receptors on CGRP Positive Neurons, the Expression of which is Dramatically Increased by Inflammation
September 2023
IHC: Human Trigeminal Ganglia Possess Oxytocin Receptors on CGRP Positive Neurons: Expression Increased by Inflammation
June 2023
ATC: aCD154mAb (TNX-1500) Alone, or in Combination with Rapamycin, MMF, or aCD28mAb (VEL-101) Prolongs Cynomolgus Cardiac Allograft Survival
June 2023
ATC: Fc-Modified Anti-CD154 Mab Induced Long Term Renal Allograft Survival without Thromboembolic Complications
June 2023
ATC: Efficacy of CD154 Blockade with TNX-1500 to Prevent Heart Allograft Immune Injury
June 2023
A Randomized Placebo-Controlled Multicenter Trial of Monotherapy with TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for Treatment of Major Depressive Disorder (MDD)
April 2023
AACR: MDSC-targeted TFF2-MSA Synergizes with PD-1 Blockade Therapy in Advanced Gastric Cancer Models
April 2023
AACR: MDSC-Targeted mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in Anti-PD-1 Treated MC38 and CT26.wt Murine Colorectal Cancer Models
April 2023
TNX-801: A Novel Mpox Vaccine: Live, Replicating, Attenuated Orthopoxvirus (Horsepox) Vaccine
April 2023
The Development of Horsepox Virus as a Vaccine Platform: Evaluation of TNX-1800 as a SARS-CoV-2 Vaccine
March 2023
The 5th International Congress on Controversies in Fibromyalgia
March 2023
Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia: Results from the Randomized, Placebo-Controlled RELIEF Trial
March 2023
TNX-2900 — Rare Disease Summit, Philadelphia, 23-March-2023
March 2023
mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in an Anti-PD-1 Treated MC38 Colorectal Cancer Model by Targeting MDSCs
February 2023
TNXP Presentation for BIO and Solve ME Event
January 2023
Primary vs Secondary Sex Hormones and Migraine
January 2023
Targeting the Wnt/β-catenin pathway as a broad-spectrum antiviral strategy
December 2022
Live Virus Smallpox and Monkeypox Vaccine
November 2022
Platform for Generating Fully Human anti-SARS-CoV-2 Spike Therapeutic Monoclonal Antibodies
November 2022
In Vitro Impact of Oxytocin on Human Sensory Neurons
September 2022
Retrospective Observational Database Study of Patients with Long COVID with Multi-Site Pain, Fatigue, and Insomnia: A Real-World Analysis of Symptomatology and Opioid Use
September 2022
Monotherapy with TNX-1500, an Fc-modified Anti-CD154 mAb, Prolongs Cardiac Allograft Survival in Cynomolgus Monkeys
September 2022
Long-term (>1 year) Rejection/TMA Free Survival of Kidney Xenografts with Triple Xenoantigen Knockout and Multiple Human Transgenes in Nonhuman Primates
September 2022
Long-term Rejection Free Renal Allograft Survival with Fc-modified Anti-CD154 Antibody Monotherapy in Nonhuman Primates
June 2022
TNX-1500, an Fc-modified Anti-CD154 Antibody,
Prolongs Nonhuman Primate Cardiac Allograft Survival
June 2022
Long Term Rejection Free Renal Allograft Survival with Fc Modified Anti CD154 Antibody Monotherapy in Nonhuman Primates
June 2022
Novel Targetable Pathways in Costimulation Pathway Blockade
June 2022
The Virus-host Interface: A Treasure Trove of Novel Antiviral Targets
June 2022
Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox
November 2021
TNX-601 CR*: a Once-Daily Formulation of Tianeptine in Development for the Treatment of Major Depressive Disorder
November 2021
TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Trial
July 2020
Intranasal (IN) Oxytocin Relieves Pain and Depressive Behavior in a Rodent Model of Mild Traumatic Brain Injury (TBI)
June 2021
Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Trial
June 2021
Effect of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) on PTSD Sleep-Dependent Emotional Memory Processing: Retrospective Analysis of Phase 2 and 3 Trial Results in Military-Related and Civilian PTSD
June 2020
Stabilized recombinant trefoil factor 2 (TFF2-CTP) enhances anti-tumor activity of PD-1 blockade in mouse models of colorectal cancer
January 2020
Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox*
November 2019
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome
May 2019
Steady-State Pharmacokinetic Properties of a Sublingual Formulation of Cyclobenzaprine (CBP) HCl (TNX-102 SL*): Comparison to Simulations of Oral Immediate Release CBP
November 2018
Differential Treatment Effects of a Sublingual Formulation of Cyclobenzaprine (TNX-102 SL*) on Dissociative Symptoms of Derealization and Depersonalization in a Military-Related PTSD
November 2018
Time Since Trauma in PTSD: Phase 3 Multi-Center, Double-Blind, Placebo-Controlled Trial of TNX-102 SL*,a Sublingual Formulation of Cyclobenzaprine, in Military-Related PTSD (Study TNX-CY-P301)
August 2017
Phase 2 Trial of a Low Dose, Bedtime, Proprietary Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Mediators and Moderators of Treatment Response
August 2017
Efficacy and Safety of a Low Dose, Bedtime, Proprietary, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL#) for the Treatment of Military-Related PTSD: Study Protocol of a Phase 3 Randomized Placebo-Controlled Trial (P301)
August 2018
Effect of Time Since Trauma on Response to TNX-102 SL* (Cyclobenzaprine Sublingual Tablets) in Military-Related PTSD: Results of Two Double-Blind Randomized Placebo-Controlled Studies
May 2018
Including Suicidal Individuals in Treatment Trials: Treatment of Military-Related PTSD with TNX-102 SL, a Novel Sublingual Formulation of Cyclobenzaprine Hypothesized to Address PTSD through Improvement in Sleep Quality
June 2017
Bedtime Sublingual Transmucosal Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response
May 2017
Bedtime Sublingual Transmucosal Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response
May 2017
Phase 2 Multisite Double-Blind Placebo-Controlled Trial of TNX-102 SL in Military-Related Posttraumatic Stress Disorder (PTSD): Mediators and Moderators of Treatment Response
December 2016
The AtEase Study: A Phase 2 Multicenter Randomized Clinical Trial of the Safety and Efficacy of TNX – 102 SL in the Treatment of Military-Related PTSD
November 2016
Low-Dose Sublingual Cyclobenzaprine (TNX-102 SL) in Military-Related PTSD: Results of a Phase 2 Randomized, Placebo-Controlled Multicenter Trial
November 2016
The Efficacy and Safety of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine, for the Treatment of Military-Related PTSD
October 2016
A Retrospective Analysis of the Efficacy of TNX-102 SL in Military-Related PTSD: Determining the Appropriate Severity Threshold for Trial Entry Using the Clinician-Administered PTSD Scale for DSM-5
October 2016
Tonix PTSD Awareness Day – October 26, 2016: Dr. Gregory Sullivan – Results of the Phase 2 “AtEase Study” in Military-Related PTSD
October 2016
Tonix PTSD Awareness Day – October 26, 2016: Dr. Jonathan Davidson – A Review of Pharmacotherapy for PTSD
October 2016
Tonix PTSD Awareness Day – October 26, 2016: Dr. Thomas A. Mellman – Focus on Sleep and PTSD Treatment Populations
August 2016
The AtEase Study: Efficacy and Safety of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD
June 2016
TNX-102 SL for the Treatment of Fibromyalgia — Comparison of 30% Pain Respondent Analysis with Omeract Draft Composite Responder Endpoint Analyses
June 2016
A Randomized Placebo-Controlled Multicenter Trial of a Low-Dose Bedtime Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD
May 2016
A Randomized Placebo-Controlled Multicenter Trial of a Low-Dose Bedtime Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD
March 2016
Rapid Sublingual Absorption of Cyclobenzaprine (CBP) with Basifying Agents: Prospect for Bedtime Treatment of Fibromyalgia Syndrome (FM) Presentation Number: LB-026
November 2015
Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL)
November 2015
Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL)
November 2015
Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study
November 2015
An Evaluation of the Efficacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) in Military-Related PTSD
November 2015
Comparative Neuropharmacology of Therapeutic Agents Targeting Posttraumatic Stress Disorder
June 2015
Serotonin Receptor Profiles of Bedtime Pharmacotherapies Targeting Posttraumatic Stress Disorder (PTSD)
June 2015
TNX-102 SL for Treatment of Fibromyalgia: Approaches to Pain Measurement
June 2015
TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization
August 2015
The (R)-isomer of isometheptene, decreases trigeminal sensitivity in the Inflammatory Soup and Spontaneous Trigeminal Allodynia rat models
August 2015
The AtEase Study: An Evaluation of the Efficacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD
August 2015
(R)-isometheptene* (IMH) Binds to the Imidazoline-1 Receptor and (S)-IMH increases Blood Pressure: Potentially Superior Benefit-to-Risk Ratio for (R)-IMH as an Analgesic for Headache
November 2013
Cyclobenzaprine (CBP) and its Major Metabolite Norcyclobenzaprine (nCBP) are Potent Antagonists of the Serotonin Receptor 2A, Histamine H1 and α-Adrenergic Receptors: Mechanistic and Safety Implications…
LOAD MORE
